Brokerages Set VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Target Price at $0.95

Shares of VistaGen Therapeutics, Inc. (NASDAQ:VTGN) have been assigned a consensus rating of “Reduce” from the five ratings firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and four have issued a hold rating on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $0.95.

VTGN has been the subject of several analyst reports. Wall Street Zen lowered VistaGen Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Weiss Ratings restated a “sell (d-)” rating on shares of VistaGen Therapeutics in a research report on Wednesday, January 21st.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of VTGN. Bank of America Corp DE increased its position in shares of VistaGen Therapeutics by 1,068.0% during the fourth quarter. Bank of America Corp DE now owns 21,141 shares of the company’s stock valued at $62,000 after acquiring an additional 19,331 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of VistaGen Therapeutics in the 1st quarter worth approximately $25,000. Marshall Wace LLP purchased a new position in shares of VistaGen Therapeutics during the 2nd quarter worth approximately $69,000. Jane Street Group LLC purchased a new position in shares of VistaGen Therapeutics during the 2nd quarter worth approximately $190,000. Finally, AdvisorShares Investments LLC increased its holdings in VistaGen Therapeutics by 1.9% in the 3rd quarter. AdvisorShares Investments LLC now owns 206,998 shares of the company’s stock valued at $735,000 after purchasing an additional 3,884 shares during the last quarter. Institutional investors and hedge funds own 78.39% of the company’s stock.

VistaGen Therapeutics Trading Down 5.4%

VistaGen Therapeutics stock opened at $0.57 on Tuesday. The company has a 50-day moving average price of $0.59 and a 200 day moving average price of $1.91. VistaGen Therapeutics has a 12-month low of $0.43 and a 12-month high of $5.14. The stock has a market cap of $22.58 million, a P/E ratio of -0.30 and a beta of 0.33.

VistaGen Therapeutics (NASDAQ:VTGN) last posted its quarterly earnings results on Thursday, February 12th. The company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.06. The firm had revenue of $0.30 million during the quarter, compared to analysts’ expectations of $0.14 million. As a group, analysts forecast that VistaGen Therapeutics will post -1.88 EPS for the current year.

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.